These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32829493)

  • 21. Psoriasis Onset during Anti-TNF Treatment for Hidradenitis Suppurativa: Successful Remission of Both Conditions with Secukinumab.
    Kontochristopoulos G; Kanni T; Marnelakis I; Agiasofitou E; Liakou A; Rigopoulos D
    Skinmed; 2023; 21(1):57-58. PubMed ID: 36987833
    [No Abstract]   [Full Text] [Related]  

  • 22. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
    Gottlieb A; Natsis NE; Kerdel F; Forman S; Gonzalez E; Jimenez G; Hernandez L; Kaffenberger J; Guido G; Lucas K; Montes D; Gold M; Babcock C; Simard J
    J Invest Dermatol; 2020 Aug; 140(8):1538-1545.e2. PubMed ID: 32004568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
    Moul DK; Korman NJ
    Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
    [No Abstract]   [Full Text] [Related]  

  • 24. Complications of hidradenitis suppurativa.
    Yuan JT; Naik HB
    Semin Cutan Med Surg; 2017 Jun; 36(2):79-85. PubMed ID: 28538749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secukinumab-induced paradoxical hidradenitis suppurativa.
    Navarro-Triviño FJ; Sanchez-Parera R; Ruiz-Villaverde R
    Dermatol Ther; 2020 Jan; 33(1):e13150. PubMed ID: 31670893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.
    Chiricozzi A; Garcovich S; Malvaso D; Giovanardi G; Peris K
    Int J Dermatol; 2020 Nov; 59(11):1423-1424. PubMed ID: 32966593
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients).
    Melgosa Ramos FJ; García Ruiz R; Estébanez Corrales A; Mateu Puchades A
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e517-e519. PubMed ID: 36268711
    [No Abstract]   [Full Text] [Related]  

  • 28. Secondary gastrointestinal amyloid A amyloidosis possibly caused by hidradenitis suppurativa.
    Kochi S; Esaki M; Kurahara K
    Dig Endosc; 2018 Sep; 30(5):681. PubMed ID: 29933503
    [No Abstract]   [Full Text] [Related]  

  • 29. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.
    Nikolakis G; Kreibich K; Vaiopoulos A; Kaleta K; Talas J; Becker M; Zouboulis CC
    F1000Res; 2021; 10():381. PubMed ID: 34540202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hidradenitis suppurativa managed with adalimumab.
    Yamauchi PS; Mau N
    J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of hidradenitis suppurativa and familial Mediterranean fever: A case series of 6 patients.
    Abbara S; Georgin-Lavialle S; Stankovic Stojanovic K; Bachmeyer C; Senet P; Buob D; Audia S; Delcey V; Fellahi S; Bastard JP; Awad F; Legendre M; Amselem S; Grateau G
    Joint Bone Spine; 2017 Mar; 84(2):159-162. PubMed ID: 27238193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review.
    Alzaga Fernandez AG; Demirci H; Darnley-Fisch DA; Steen DW
    Cornea; 2010 Oct; 29(10):1189-91. PubMed ID: 20628295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa.
    Konda S; Shetty N; Friedman B; Veenstra J
    BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35580946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases).
    Reguiaï Z; Fougerousse AC; Maccari F; Bécherel PA
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):e750-e751. PubMed ID: 32401354
    [No Abstract]   [Full Text] [Related]  

  • 37. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.
    Casseres RG; Prussick L; Zancanaro P; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Au SC; Alomran A; Abdat R; Abudu M; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
    J Am Acad Dermatol; 2020 Jun; 82(6):1524-1526. PubMed ID: 32044410
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report.
    Thorlacius L; Theut Riis P; Jemec GBE
    Br J Dermatol; 2018 Jul; 179(1):182-185. PubMed ID: 28654150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities.
    Crowley JJ; Mekkes JR; Zouboulis CC; Scheinfeld N; Kimball A; Sundaram M; Gu Y; Okun MM; Kerdel F
    Br J Dermatol; 2014 Dec; 171(6):1561-5. PubMed ID: 24842009
    [No Abstract]   [Full Text] [Related]  

  • 40. New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.
    Molinelli E; Gioacchini H; Sapigni C; Diotallevi F; Brisigotti V; Rizzetto G; Offidani A; Simonetti O
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.